Philip Tsai

Philip Tsai is currently the Chief Technology Officer at Immunome, Inc., a position held since 2024. Previously, they served in various leadership roles, including Vice President of Process Sciences and Vice President of Biologics Development at Seagen from 2015 to 2018, where they oversaw process and analytical development for therapeutic products. Philip began their career as a Process Engineer at Biogen from 1995 to 2002. They hold a Master’s and Ph.D. in Biochemical Engineering from the California Institute of Technology and a Bachelor of Science in Chemical Engineering from the University of Illinois at Urbana-Champaign, along with additional education in Biotechnology from Eidgenössische Technische Hochschule Zürich.